Regulatory Travere claims first FDA OK in rare kidney disease FSGS PharmaphorumShrugging off an earlier phase 3 disappointment, Travere's Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.RegulatoryRare DiseaseRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS. RegulatoryRare DiseaseRead full story Post navigation Previous: Novo Nordisk and OpenAI forge alliance to drive speedy drug developmentNext: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
